abciximab
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Myocardial Infarction
Conditions
Myocardial Infarction
Trial Timeline
Apr 1, 2006 → Dec 1, 2008
NCT ID
NCT00354406About abciximab
abciximab is a approved stage product being developed by Eli Lilly for Myocardial Infarction. The current trial status is completed. This product is registered under clinical trial identifier NCT00354406. Target conditions include Myocardial Infarction.
What happened to similar drugs?
20 of 20 similar drugs in Myocardial Infarction were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00178451 | Phase 1/2 | Withdrawn |
| NCT00440895 | Approved | Completed |
| NCT00440778 | Approved | Completed |
| NCT00420030 | Approved | Completed |
| NCT00354406 | Approved | Completed |
| NCT00167765 | Phase 3 | Terminated |
| NCT00126139 | Phase 3 | Terminated |
| NCT00073372 | Phase 3 | Terminated |
| NCT00169819 | Approved | Completed |
Competing Products
20 competing products in Myocardial Infarction